Gliclazide Use in Renal Impairment

Dosing Considerations

The American Journal of Kidney Diseases recommends gliclazide as a preferred sulfonylurea in renal impairment because it lacks active metabolites and does not require dose adjustment until eGFR falls below 30 mL/min/1.73 m² 1
No dose adjustment is required for gliclazide when eGFR is ≥30 mL/min/1.73 m², and standard doses of 80-320 mg daily can be used 1
Dose reduction is recommended when eGFR is <30 mL/min/1.73 m², due to substantially elevated hypoglycemia risk 1, 2

The Kidney International guidelines suggest considering alternative agents such as DPP-4 inhibitors or insulin when eGFR is <30 mL/min/1.73 m² 3
Metformin remains a first-line agent with dose adjustment when eGFR is 30-44 mL/min/1.73 m², and SGLT2 inhibitors provide cardiovascular and renal protection (Grade 1A recommendation) 3

The American Journal of Kidney Diseases recommends monitoring blood glucose closely when initiating or continuing gliclazide in patients with eGFR <60 mL/min/1.73 m², and reassessing eGFR at least every 3-6 months when eGFR is 30-59 mL/min/1.73 m² 1, 3
Educating patients on hypoglycemia recognition and management is crucial when using gliclazide, especially in patients with renal impairment 1

The American Journal of Kidney Diseases advises avoiding first-generation sulfonylureas entirely, as they accumulate significantly in renal impairment 1
Temporarily discontinuing gliclazide during intercurrent illness can help prevent acute kidney injury and medication accumulation 2